Skyrizi vs. Taltz

• Are Skyrizi and Taltz the Same Thing?
• What Are Possible Side Effects of Skyrizi?
• What Are Possible Side Effects of Taltz?
• What Is Skyrizi?
• What Is Taltz?
• What drugs interact with Skyrizi?
• What drugs interact with Taltz?
• How Should Skyrizi Be Taken?
• How Should Taltz Be Taken?

Skyrizi (risankizumab-rzaa) and Taltz (ixekizumab) are used to treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Skyrizi and Taltz are interleukin antagonists that target different proteins. Skyrizi is an interleukin-23 antagonist and Cosentyx is an interleukin-17A antagonist.

Side effects of Skyrizi and Taltz that are similar include upper respiratory infections (runny or stuffy nose, rhinovirus infections), injection site reactions (bruising, redness, fluid leakage, bleeding, infection, inflammation, irritation, pain, itching, swelling, warmth), and tinea infections (such as ringworm, athlete's foot, and jock itch).

Side effects of Skyrizi that are different from Taltz include headache and fatigue.

Side effects of Taltz that are different from Skyrizi include nausea.

Both Skyrizi and Taltz may interact with “live” vaccines.

Taltz may also interact with warfarin and cyclosporine.

Side effects of Skyrizi include:

• upper respiratory infections,
• headache,
• fatigue,
• injection site reactions (bruising, redness, fluid leakage, bleeding, infection, inflammation, irritation, pain, itching, swelling, warmth), and
• tinea infections (such as ringworm, athlete's foot and jock itch)

Common side effects of Taltz include:

• injection site reactions (redness, pain)
• upper respiratory tract infections (runny or stuffy nose, rhinovirus infections)
• nausea, and
• fungal infections (ringworm, athlete's foot and jock itch)

Skyrizi (risankizumab-rzaa) is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Taltz (ixekizumab) injection is a humanized interleukin-17A antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Skyrizi may interact with "live" vaccines. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Skyrizi; it is unknown how it would affect a fetus. It is unknown if Skyrizi passes into breast milk. Consult your doctor before breastfeeding.

Taltz may interact with "live" vaccines, warfarin, and cyclosporine. Tell your doctor all medications and supplements you use and all vaccines you recently received.

The dose of Skyrizi is 150 mg (two 75 mg injections) administered by subcutaneous injection at Week 0, Week 4 and every 12 weeks thereafter.

The recommended dose of Taltz is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.